NVE Corporation's stock fell 33.68% following its October 21, 2026 disclosure of a 47% revenue drop and significant declines in sales, gross profit, and earnings per share for Q2 fiscal 2027. The company cited inventory adjustments and a sharp decrease in defense product sales as reasons. Law firm Glancy Prongay Wolke & Rotter LLP is investigating potential securities fraud claims on behalf of investors who lost money, questioning if the company provided full and accurate information before the disclosure. Investors affected can contact the firm to explore recovery options.
NVE Corporation's recent stock drop is context for readers following health-sector stocks. Of 150 health-sector US stocks on Pluang, 106 rose and 43 fell today. Notable movers include TLRY at USD 2.96 with +11.70% change and 96% sell activity, MDLN at USD 37.88 with +11.12% change and 98% buy activity, and CVS at USD 81.26 with -11.10% change and 91% buy activity. Data is as of Nov 04, 2026 22:12 WIB.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
